Corrigendum to “What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?” [Int. Immunopharmacol. 105 (2022) 108542] (International Immunopharmacology (2022) 105, (S1567576922000261), (10.1016/j.intimp.2022.108542))
CorrectionAçık Erişim
Özet
The authors express their apologies for the minor errors mentioned below. First, the authors misidentified the significant p-values they show in Tables 1–8. Second, they miscalculated the 95% CI breakpoints of the PT value in Table 7. The authors report that the level of significance for p = 0.000 in Tables 1–8 is p < 0.001. They also state that the 95% CI values of the PT parameter specified in Table 7 are 1.63-2.56. These corrections do not affect the interpretation of the data or the conclusions drawn. The authors apologize to the journal and readers for these unintentional errors. © 2023 Elsevier B.V.
Anahtar Kelimeler
RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11873Resmi atıflarda kullanılan kalıcı adresTam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Huyut, Mehmet Tahir | |
| dc.contributor.author | Huyut, Zübeyir | |
| dc.contributor.author | Ilkbahar, Fatih | |
| dc.contributor.author | Mertoğlu, Cuma | |
| dc.date.accessioned | 2026-10-18T20:26:51.892438144Z | |
| dc.date.available | 2026-10-18T20:26:51.892438144Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | The authors express their apologies for the minor errors mentioned below. First, the authors misidentified the significant p-values they show in Tables 1–8. Second, they miscalculated the 95% CI breakpoints of the PT value in Table 7. The authors report that the level of significance for p = 0.000 in Tables 1–8 is p < 0.001. They also state that the 95% CI values of the PT parameter specified in Table 7 are 1.63-2.56. These corrections do not affect the interpretation of the data or the conclusions drawn. The authors apologize to the journal and readers for these unintentional errors. © 2023 Elsevier B.V. | |
| dc.identifier.doi | 10.1016/j.intimp.2023.110821 | |
| dc.identifier.eissn | 1878-1705 | |
| dc.identifier.issn | 1567-5769 | |
| dc.identifier.pmcid | PMC11021217 | |
| dc.identifier.pmid | 37625945 | |
| dc.identifier.scopus | 2-s2.0-85168748208 | |
| dc.identifier.startpage | 110821 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/11873 | |
| dc.identifier.volume | 123 | |
| dc.identifier.wos | WOS:001083709600001 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | International Immunopharmacology | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | erratum | |
| dc.title | Corrigendum to “What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?” [Int. Immunopharmacol. 105 (2022) 108542] (International Immunopharmacology (2022) 105, (S1567576922000261), (10.1016/j.intimp.2022.108542)) | |
| dc.type | Correction | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 0 | |
| rdl.citation.wos | 0 | |
| rdl.department | Erzincan Binali Yıldırım University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Erzincan, Türkiye. Electronic address: tahir.huyut@erzincan.edu.tr. | Erzincan Binali Yıldırım University, Faculty of Medicine, Department of Clinical Biochemistry, Erzincan, Türkiye | |
| rdl.department | Inonu University, Faculty of Medicine, Department of Clinical Biochemistry, Malatya, Türkiye. | |
| rdl.oa.status | green | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
